Health Care

Hospitals Are Facing Margin Pressure…

Key Portfolio Highlights The S&P 500 has started 2019 with a bang as dovish cooing from the Fed has proven a tonic for equities. While we have not entirely retraced the path to the early-autumn highs, our strategy of staying cyclically exposed, based on our view of an absence of a…

Highlights After rising for thousands of years, human intelligence has begun to decline in developed economies. This can be seen in falling IQ scores and a decline in math and science test scores. Environmental factors appear to account for the bulk of this decline, but no one knows what these…

After rising for thousands of years, human intelligence has begun to decline in developed economies. This can be seen in falling IQ scores and a decline in math and science test scores. Environmental factors appear to account for the bulk of this decline, but no one knows what these factors…

Highlights Global equity markets have managed to recoup some of last year’s plunge since we upgraded stocks to overweight in late December. The equity rally has been tentative, however, and so far feels more like a technical bounce from oversold levels than a resumption of the bull market.…

Highlights The Eurostoxx600’s short bursts of outperformance require either global technology to underperform or the euro to underperform. EM’s short bursts of outperformance usually coincide with the global healthcare sector’s short bursts of underperformance. Remain tactically overweight to…

Highlights All of our recent investment recommendations have performed very strongly but have further to go: 1.   Own a combination of European banks plus U.S. T-bonds. 2.   Overweight EM versus DM. 3.   Overweight European versus U.S. equities. 4.  …

Highlights Our leading indicator for China’s old economy continues to point to slower growth over the coming months, which is consistent with the bearish message from China’s housing market and forward-looking export indicators. We would caution investors against interpreting the recent…

  Neutral The pharma space has been exploding with merger mania as the largest pharma deal ever (Bristol-Myers Squibb buying Celgene for approximately $90 billion) was followed up by Eli Lilly acquiring Loxo Oncology for nearly $8 billion. These fall on the back of other notable global…